Camrelizumab and Apatinib

DRUG6 trials

Sponsors

ShiYue Li, Chinese Academy of Medical Sciences, Fudan University, Xuanwu Hospital, Beijing, Guohui Xu

Conditions

ApatinibCamrelizumabChemotherapy EffectChordomaHepato Cellular Carcinoma (HCC)Lung CancerSarcomaThyroid Cancer

Phase 1

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

ShiYue LiLung Cancer

Start: 2019-12-31End: 2022-12-31Target: 20Updated: 2019-12-17

Phase 2

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Chinese Academy of Medical SciencesSarcoma

Start: 2020-07-01End: 2021-12-31Target: 20Updated: 2020-06-25

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Fudan UniversityThyroid Cancer

Start: 2020-12-01End: 2023-12-31Target: 31Updated: 2020-11-03

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

RecruitingNCT06140732

Xuanwu Hospital, BeijingChemotherapy Effect, Chordoma

Start: 2023-10-30End: 2026-01-31Target: 30Updated: 2023-11-20

Phase 3

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

RecruitingNCT06485466

Guohui XuApatinib, Camrelizumab, Transarterial Chemoembolization +1

Start: 2024-07-01End: 2028-06-30Target: 101Updated: 2024-07-03

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

RecruitingNCT07267806

Linhui PengChemotherapy Effect, Hepato Cellular Carcinoma (HCC)

Start: 2025-10-31End: 2032-10-31Target: 326Updated: 2025-12-16